Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s | BioSpace
https://www.biospace.com/article/bi...n-leqembi-s-subcutaneous-bla-for-alzheimer-s/
Biogen and Eisai on Monday announced that they have missed their March 2024 target of filling a Biologics License Application for a subcutaneous formulation of their Alzheimer’s disease therapy Leqembi (lecanemab), being proposed as a weekly maintenance regimen.
https://www.biospace.com/article/bi...n-leqembi-s-subcutaneous-bla-for-alzheimer-s/
Biogen and Eisai on Monday announced that they have missed their March 2024 target of filling a Biologics License Application for a subcutaneous formulation of their Alzheimer’s disease therapy Leqembi (lecanemab), being proposed as a weekly maintenance regimen.